Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

BACKGROUND AND OBJECTIVE: Previous studies of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents, and severe atopic dermatitis in children aged 6 to < 12 years demonstrate no clinically important changes in laboratory parameters. The objective of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Siegfried, Elaine C., Cork, Michael J., Wollenberg, Andreas, Arkwright, Peter D., Gonzalez, Mercedes E., Lockshin, Benjamin, Chen, Zhen, Bansal, Ashish, Levit, Noah A., Prescilla, Randy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810566/
https://www.ncbi.nlm.nih.gov/pubmed/36529811
http://dx.doi.org/10.1007/s40272-022-00553-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810566/
https://www.ncbi.nlm.nih.gov/pubmed/36529811
http://dx.doi.org/10.1007/s40272-022-00553-8

Ejemplares similares